World Workshop on Oral Medicine VII: Immunobiologics for salivary gland disease in Sjögren's syndrome: A systematic review.
Antirheumatic Agents
/ therapeutic use
Biological Factors
/ therapeutic use
Congresses as Topic
Humans
Observational Studies as Topic
Quality of Life
Randomized Controlled Trials as Topic
Rituximab
/ therapeutic use
Saliva
/ chemistry
Salivary Gland Diseases
/ pathology
Salivary Glands
/ physiopathology
Sjogren's Syndrome
/ drug therapy
Visual Analog Scale
Xerostomia
/ physiopathology
Sjogren's syndrome
biologic agents
salivary flow
xerostomia
Journal
Oral diseases
ISSN: 1601-0825
Titre abrégé: Oral Dis
Pays: Denmark
ID NLM: 9508565
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
21
01
2019
revised:
01
02
2019
accepted:
02
02
2019
entrez:
30
5
2019
pubmed:
30
5
2019
medline:
3
1
2020
Statut:
ppublish
Résumé
This systematic review evaluated the efficacy of immunobiologics for the management of oral disease in Sjögren's syndrome (SS). MEDLINE Seventeen studies (11 randomized controlled trials and 6 observational studies) met inclusion criteria. Rituximab showed efficacy in improving salivary gland function but not xerostomia. Abatacept showed promise in improving both xerostomia and salivary flow. Belimumab exhibited long-term improvement of salivary flow and subjective measures. The novel agent CFZ533 improved both disease activity and patient-reported indexes. There is strong evidence pointing to the efficacy of rituximab in the management of oral disease in SS. Future controlled trials may elucidate the efficacy of belimumab and abatacept. The new drug CFZ533 is a promising alternative for the management of SS and its salivary gland involvement. In considering these agents, the promise of efficacy must be balanced against the harmful effects associated with biologic agents.
Identifiants
pubmed: 31140693
doi: 10.1111/odi.13062
pmc: PMC6544171
mid: NIHMS1012250
doi:
Substances chimiques
Antirheumatic Agents
0
Biological Factors
0
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Systematic Review
Langues
eng
Pagination
102-110Subventions
Organisme : Intramural NIH HHS
ID : Z99 DE999999
Pays : United States
Organisme : Colgate-Palmolive
Organisme : Oral Diseases
Organisme : European Association of Oral Medicine
Organisme : American Academy of Oral Medicine
Organisme : Xerostom
Organisme : Intramural NIH HHS
ID : ZIA DE000747-02
Pays : United States
Organisme : The World Dental Education Foundation
Organisme : Unilever
Organisme : NIDCR NIH HHS
ID : R13 DE027613
Pays : United States
Organisme : Henry Schein Cares Foundation
Organisme : The British Society for Oral Medicine
Organisme : AFYX
Organisme : The National Institute of Dental and Craniofacial Research
Informations de copyright
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. All rights reserved.
Références
N Engl J Med. 2000 Jun 22;342(25):1887-92
pubmed: 10861325
Ann Rheum Dis. 2002 Jun;61(6):554-8
pubmed: 12006334
J Rheumatol. 2004 Jan;31(1):96-101
pubmed: 14705226
Arthritis Rheum. 2004 Apr;50(4):1270-6
pubmed: 15077311
Arthritis Rheum. 2004 Jul;50(7):2240-5
pubmed: 15248223
Ann Rheum Dis. 2005 Jun;64(6):913-20
pubmed: 15550531
Arthritis Res Ther. 2006;8(4):R129
pubmed: 16859536
Arthritis Rheum. 2007 Mar 15;57(2):310-7
pubmed: 17330280
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Mar;103 Suppl:S57.e1-15
pubmed: 17379156
Clin Rev Allergy Immunol. 2008 Feb;34(1):124-8
pubmed: 18270866
Ann Rheum Dis. 2008 Nov;67(11):1541-4
pubmed: 18276741
Ann Rheum Dis. 2010 Jun;69(6):1103-9
pubmed: 19561361
Arthritis Rheum. 2010 Apr;62(4):960-8
pubmed: 20131246
Autoimmun Rev. 2010 Jul;9(9):609-14
pubmed: 20452466
Clin Exp Rheumatol. 2011 Jan-Feb;29(1):6-12
pubmed: 21345287
Ann Rheum Dis. 2011 Jun;70(6):968-72
pubmed: 21345815
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Arthritis Care Res (Hoboken). 2012 Apr;64(4):475-87
pubmed: 22563590
Ann Rheum Dis. 2013 Jun;72(6):1026-31
pubmed: 23264337
Arthritis Rheum. 2013 Apr;65(4):1097-106
pubmed: 23334994
Acta Dermatovenerol Croat. 2013;21(1):24-34
pubmed: 23683483
Arthritis Care Res (Hoboken). 2013 Nov;65(11):1862-8
pubmed: 23740889
Arthritis Res Ther. 2013 Oct 30;15(5):R172
pubmed: 24286296
Ann Rheum Dis. 2015 Mar;74(3):526-31
pubmed: 24347569
Ann Rheum Dis. 2014 Jul;73(7):1393-6
pubmed: 24473674
Ann Intern Med. 2014 Feb 18;160(4):233-42
pubmed: 24727841
Arthritis Rheumatol. 2015 Jun;67(6):1623-8
pubmed: 25708147
Rheumatology (Oxford). 2015 Dec;54(12):2249-56
pubmed: 26242856
PLoS One. 2016 Mar 21;11(3):e0150749
pubmed: 26998607
Arthritis Care Res (Hoboken). 2017 Apr;69(4):517-527
pubmed: 27390247
Arthritis Care Res (Hoboken). 2017 Apr;69(4):528-535
pubmed: 27390310
Rheum Dis Clin North Am. 2016 Aug;42(3):531-51
pubmed: 27431353
Mod Rheumatol. 2016 Nov;26(6):891-899
pubmed: 27459020
Expert Opin Biol Ther. 2017 Jan;17(1):63-75
pubmed: 27616561
PLoS One. 2016 Sep 23;11(9):e0162787
pubmed: 27662653
Ann Rheum Dis. 2017 Jan;76(1):9-16
pubmed: 27789466
Arthritis Rheumatol. 2017 Jul;69(7):1440-1450
pubmed: 28296257
Clin Immunol. 2017 Sep;182:62-71
pubmed: 28478105
Joint Bone Spine. 2018 Jan;85(1):15-22
pubmed: 28673789
Ann Rheum Dis. 2018 Mar;77(3):412-416
pubmed: 29275334
Front Med (Lausanne). 2018 Apr 13;5:102
pubmed: 29707540
Oral Dis. 2019 May;25(4):1027-1047
pubmed: 30086205